Legend Biotech Corp (LEGN) - Total Assets
Based on the latest financial reports, Legend Biotech Corp (LEGN) holds total assets worth $1.75 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Legend Biotech Corp - Total Assets Trend (2017–2025)
This chart illustrates how Legend Biotech Corp's total assets have evolved over time, based on quarterly financial data. Also see how much is Legend Biotech Corp worth for the company's overall valuation and market capitalisation.
Legend Biotech Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Legend Biotech Corp's total assets of $1.75 Billion consist of 71.9% current assets and 28.1% non-current assets. Review total liabilities of Legend Biotech Corp to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.0% |
| Accounts Receivable | $250.30 Million | 14.4% |
| Inventory | $32.00 Million | 1.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $74.60 Million | 4.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Legend Biotech Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LEGN share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Legend Biotech Corp's current assets represent 71.9% of total assets in 2025, a decrease from 96.7% in 2017.
- Cash Position: Cash and equivalents constituted 52.0% of total assets in 2025, up from 0.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 14.4% of total assets.
Legend Biotech Corp Competitors by Total Assets
Key competitors of Legend Biotech Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Legend Biotech Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.04 | 4.71 | 2.37 |
| Quick Ratio | 2.94 | 4.57 | 2.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $823.83 Million | $984.39 Million | $377.99 Million |
Legend Biotech Corp - Advanced Valuation Insights
This section examines the relationship between Legend Biotech Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.40 |
| Latest Market Cap to Assets Ratio | 1.98 |
| Asset Growth Rate (YoY) | 3.8% |
| Total Assets | $1.73 Billion |
| Market Capitalization | $3.44 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Legend Biotech Corp's assets above their book value (1.98x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Legend Biotech Corp's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Legend Biotech Corp (2017–2025)
The table below shows the annual total assets of Legend Biotech Corp from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.73 Billion | +3.80% |
| 2024-12-31 | $1.67 Billion | -9.65% |
| 2023-12-31 | $1.85 Billion | +38.89% |
| 2022-12-31 | $1.33 Billion | +18.89% |
| 2021-12-31 | $1.12 Billion | +55.03% |
| 2020-12-31 | $722.09 Million | +150.98% |
| 2019-12-31 | $287.71 Million | -32.94% |
| 2018-12-31 | $429.05 Million | +79.75% |
| 2017-12-31 | $238.69 Million | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more